← back to search

Yiping Zhang

Fudan University · CN
🔎 Find collaborators in Pulmonary and Respiratory Medicine · Oncology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Medicine, Internal medicine, Oncology, Chemotherapy, Lung cancer, and Chemistry.
h-index
citations
1,797
works
27
NIH funding
primary concept
email

Recent publications

First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
The Lancet Respiratory Medicine 2025cited by 2position: middledoi
Early blood-spinal cord barrier stabilization preserves peri-lesional tissue and improves recovery after SCI
bioRxiv (Cold Spring Harbor Laboratory) 2025cited by 0position: middledoi
Ferroptosis implication in environmental-induced neurotoxicity
The Science of The Total Environment 2024cited by 26position: firstdoi
Protective Effects of Laminaria japonica Polysaccharide Composite Microcapsules on the Survival of Lactobacillus plantarum during Simulated Gastrointestinal Digestion and Heat Treatment
Marine Drugs 2024cited by 9position: middledoi
Novel targets for the treatment and prevention of Alzheimer's disease in the European population, inspiration from amyloid beta and tau protein
Heliyon 2024cited by 1position: middledoi
Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Nature Cancer 2024cited by 1position: middledoi
Light-Activated Chemically Reactive Fibrous Patch Revolutionizes Wound Repair Through the Prevention of Postoperative Adhesion
Nano Letters 2023cited by 24position: middledoi
Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study
Therapeutic Advances in Medical Oncology 2023cited by 19position: middledoi
P2X7 Receptor: an Emerging Target in Alzheimer’s Disease
Molecular Neurobiology 2023cited by 16position: middledoi
A photoactive self-healing carboxymethyl chitosan-based hydrogel for accelerated infected wound healing through simultaneously modulating multiple critical tissue repair factors
International Journal of Biological Macromolecules 2023cited by 15position: middledoi
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
Nature Communications 2022cited by 149position: middledoi
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
Molecular Cancer 2022cited by 54position: middledoi
Metabolomic and Microbial Remodeling by Shanmei Capsule Improves Hyperlipidemia in High Fat Food-Induced Mice
Frontiers in Cellular and Infection Microbiology 2022cited by 21position: middledoi
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy
Cancer Communications 2022cited by 19position: middledoi
Simultaneous use of nitrate and calcium peroxide to control sulfide and greenhouse gas emission in sewers
The Science of The Total Environment 2022cited by 12position: middledoi
Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)
Cancer Research 2022cited by 10position: middledoi
Comparison of three sedation models for same‐day painless bidirectional endoscopy: A multicenter randomized controlled trial
Journal of Gastroenterology and Hepatology 2022cited by 9position: middledoi
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
Journal of Thoracic Oncology 2021cited by 306position: middledoi
Modulating adult neurogenesis affects synaptic plasticity and cognitive functions in mouse models of Alzheimer's disease
Stem Cell Reports 2021cited by 51position: middledoi
First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.
Journal of Clinical Oncology 2021cited by 45position: middledoi
Integrated metabolomics and 16S rDNA sequencing to investigate the mechanism of immune-enhancing effect of health Tonic oral liquid
Food Research International 2021cited by 18position: middledoi
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
The Lancet Respiratory Medicine 2020cited by 501position: middledoi
Copper‐Catalyzed Azide–Ynamide Cyclization to Generate α‐Imino Copper Carbenes: Divergent and Enantioselective Access to Polycyclic N‐Heterocycles
Angewandte Chemie International Edition 2020cited by 96position: middledoi
Copper‐Catalyzed Azide–Ynamide Cyclization to Generate α‐Imino Copper Carbenes: Divergent and Enantioselective Access to Polycyclic N‐Heterocycles
Angewandte Chemie 2020cited by 15position: middledoi
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
The Lancet Respiratory Medicine 2019cited by 136position: middledoi
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
Investigational New Drugs 2017cited by 64position: middledoi
Prevalence of chronic kidney disease markers: Evidence from a three-million married population with fertility desire in rural China
Scientific Reports 2017cited by 14position: middledoi
Near-infrared photoluminescence from ZnO
Applied Physics Letters 2012cited by 112position: middledoi
A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.
Journal of Clinical Oncology 2012cited by 70position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yuanfang Sun · Guangzhou University of Chinese Medicine2 papers (2021–2022)Long‐Wu Ye · Jiangsu University2 papers (2020–2020)Ze‐Shu Wang · Xiamen University2 papers (2020–2020)Xin Liu · Shandong University of Technology2 papers (2020–2020)Yang‐Bo Chen · Xiamen University2 papers (2020–2020)Zihan Tian · Xinjiang University2 papers (2023–2023)Kerong Chen · Nanjing Tech University2 papers (2023–2023)Anwei Zhou · Southwest University2 papers (2023–2023)Chao Deng · Nanjing Agricultural University2 papers (2020–2020) · 2 papers (2020–2020)Xinghai Ning · University of California, Berkeley2 papers (2023–2023)Shasha Li · Guangzhou University of Chinese Medicine2 papers (2021–2022)Xiaotong Wu · Shenzhen University2 papers (2023–2023)Shikai Yan · Jiangnan University2 papers (2021–2022)Chen Luo · Xiamen University2 papers (2020–2020)Lijing Du · Guangzhou University of Chinese Medicine2 papers (2021–2022)Tong‐Yi Zhai · Xiamen University2 papers (2020–2020)Fuzhou Hua · Nanchang University2 papers (2023–2024)Xuekun Li · Zhejiang Cancer Hospital1 papers (2021–2021) · 1 papers (2012–2012)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Pulmonary and Respiratory Medicine · Oncology →